Evaluation of translational potential of mRNA vaccine candidate antigens for pancreatic cancer: a systematic review based on clinical evidence and stratified prioritization strategies - PubMed
2 hours ago
- #pancreatic cancer
- #mRNA vaccine
- #antigen prioritization
- Pancreatic cancer has a low survival rate (13% 5-year), and mRNA vaccines are a promising new treatment direction.
- The bottleneck for mRNA vaccine clinical translation is identifying antigens with tumor specificity, functional relevance, and immunogenicity.
- The review evaluated 16 potential mRNA vaccine antigens for pancreatic cancer, selected based on aberrant tumor expression.
- Antigens were prioritized using strategies including antigen-presenting cell infiltration, immune-related cell death pathways (ferroptosis/pyroptosis), and tumor progression relevance.
- Key antigens highlighted: ADAM9 and PAK2 for high expression and roles in proliferation/invasion; SCP-1 and GAGE as cancer-testis antigens with specificity and immunogenicity; KDM5A and ANO6 for modulating ferroptosis/pyroptosis.
- Some antigens face limitations due to normal tissue expression or limited mechanistic evidence.
- The review provides a stratified framework for antigen prioritization to guide multi-antigen vaccine design and translational immunotherapy.